Jazz Pharmaceuticals

Ticker: JAZZ

Sector: Pharmaceuticals

Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (jazz) stock price, quote & news - stock analysis. jazz pharmaceuticals plcs plc. plc shares: SMG. Zymeworks shares rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. announced a deal with Jazz for its cancer drug, zanidatamab, which is currently being tested as being tested with Jazz. ZymWorks will receive $350 million from Jazz. Jazz Pharmaceuticals updated its guidance for 2021 to reflect its acquisition of GW Pharmaceuticals Inc., which closed in early May. Jazz updates 2021 guidance after closing acquisition ofGW Pharmaceuticals. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global pharmaceuticals company. The company is in the Health Care sector and Pharmaceuticals industry. Jazz Pharmaceuticals is looking for an experienced Senior Director, Global Workplace with broad responsibilities across all our sites to support continued growth. The Employees Retirement System of Texas has recently made headlines with its decision to reduce its holdings in Jazz Pharmaceutical. StockNews.com initiated coverage with a “strong-buy” rating for Jazz Pharmaceuticals. Cantor Fitzgerald maintained an “overweight” rating on the stock. The growing interest shown by institutional investors and hedge funds suggests positive sentiments. Jazz Pharmaceuticals ( NASDAQ:JAZZ – Get Free Report ) last released its quarterly earnings data on Wednesday, May 10th. CFO Renee D. Gala sold 6,000 shares of Jazz pharmaceuticals stock in a transaction on Thursday, May 18th.